Bluefish expands in India
Bluefish Pharmaceuticals, a Swedish generic pharmaceutical company makes major investments in R&D in India to expand the product portfolio as product sales exceeding SEK 200 bn come off patent in Europe during the next three years.
Through collaborations, Bluefish has access to advanced drug delivery technologies that will enhance the IP of the product portfolio. Initially, the focus of the R&D investment will be in three areas; specialty generics, controlled release technologies and fixed dose combinations.
“Our strengthened presence in India allows us to access the competence, skills and technologies available in the Indian pharmaceutical market. Over the next few years, we expect to invest approximately SEK 50 million in different R&D projects ”, says Karl Karlsson, founder and CEO of Bluefish Pharmaceuticals.
To support the expanded Indian operations, Bluefish has hired Dr Ashwani Kumar as the new CEO of Bluefish India. Dr Kumar was previously Head of Global Strategic Partnering at Medreich Pharmaceuticals, an Indian pharmaceuticals company. Dr Kumar has spent the last 20 years in various positions with both American and Indian companies.
“Bluefish capabilities in marketing and regulatory, combined with product development in India is a very exciting business model. I look forward to building the India operations into a strong and integrated part of Bluefish global business”, says Dr Ashwani Kumar, new CEO of Bluefish India.
Fur further information, please contact CEO Director Karl Karlsson,phone +46 8 6795070
Bluefish Pharmaceuticals AB is a Swedish pharmaceutical company that licenses, develops,manufactures and markets mainly generic pharmaceutical products. Low prices are maintained through efficient production and distribution. Bluefish has a wholly‐owned subsidiary in Chennai,India, focusing on product development and production. The company is owned by its founder Karl Karlsson, together with a number of investment funds and private investors.